Articles related to ANTIPSYCHOTICS

The FDA’s approval of brexpiprazole for Alzheimer’s-related agitation has sparked a debate over its efficacy and safety, raising concerns that extend beyond this specific drug to the integrity of the regulatory process itself.

This retrospective cohort study provides evidence that the risk profiles for in-hospital adverse events are similar among haloperidol and atypical antipsychotics in older patients with postoperative delirium.

Explore the clinical insights into lumateperone, a second-generation antipsychotic showing promise in treating schizophrenia, and learn how understanding effect sizes can guide your treatment decisions.

The recent FDA approval of brexpiprazole for Alzheimer’s dementia patients has ignited concerns among healthcare professionals. Physicians are urged to carefully consider the drug’s minimal efficacy and increased mortality risk in their treatment decisions.

Explore the latest research on non-dopaminergic mechanisms for schizophrenia treatment, revealing innovative approaches that may lead to more effective and well-tolerated therapies.

The latest systematic review on olanzapine for schizophrenia treatment has defined a therapeutic reference range of 20-40 ng/mL, offering insight into optimal efficacy and tolerable levels. Explore the full study to understand how these findings can inform clinical practice and patient care.